Zuberbier T, Aberer W, Burtin B, Rihoux J P, Czarnetzki B M
Department of Dermatology, University Clinics Rudolf Virchow, Freie Universität Berlin, Germany.
Acta Derm Venereol. 1995 Mar;75(2):147-9. doi: 10.2340/0001555575147149.
In order to examine the efficacy of cetirizine in cholinergic urticaria, we studied 24 patients in a double-blind crossover design during 3-week treatment periods, with either 10 or 20 mg/d cetirizine or placebo. The placebo period was always placed in between the two verum treatments to allow for a washout of the drug. Evaluation of the patients' daily symptom scores based on itching, erythema and whealing showed a highly significant improvement (p < 0.01). The percentage of days with mild or no symptoms was also increased significantly with the drug (p < 0.05). Except for whealing (p < 0.05), no significant differences between the two dosages of cetirizine could be determined. Since antihistamines have previously been shown to be frequently unsatisfactory in the treatment of cholinergic urticaria, the present data are encouraging regarding the control of symptoms in this condition.
为了研究西替利嗪治疗胆碱能性荨麻疹的疗效,我们采用双盲交叉设计,对24例患者进行了为期3周的治疗,分别给予10mg/d或20mg/d的西替利嗪或安慰剂。安慰剂期总是置于两次真药治疗之间,以便药物洗脱。基于瘙痒、红斑和风团对患者每日症状评分的评估显示有高度显著的改善(p<0.01)。用药后症状轻微或无症状的天数百分比也显著增加(p<0.05)。除风团外(p<0.05),两种剂量的西替利嗪之间未发现显著差异。由于先前已证明抗组胺药在治疗胆碱能性荨麻疹方面常常不尽人意,因此目前的数据对于控制这种疾病的症状是令人鼓舞的。